Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen

Aksoy, Evrim Kahramanoğlu; Sapmaz, Ferdane; Göktaş, Zeynep; Uzman, Metin; Nazlıgül, Yaşar

doi:10.1159/000484930

Cited by 13 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bismuth‐containing quadruple therapy could partially overcome antibiotic resistance. However, AEs occurred in more than 50% of the levofloxacin‐containing bismuth quadruple therapy and standard bismuth‐containing quadruple therapy, compared with 26.2% in triple therapy 22 . There were also many competing conditions when it came to the elderly or people with multiple diseases compared to younger ones, considering the possibility of interaction with concomitant medicines 23,24 .…”

Section: Discussionmentioning

confidence: 99%

Rabeprazole‐amoxicillin dual therapy as first‐line treatment for H pylori eradication in special patients: A retrospective, real‐life study

Gao

Deng

et al. 2020

Helicobacter

View full text Add to dashboard Cite

Background The currently recommended quadruple regimens for Helicobacter pylori infection might not be appropriate for every patient, especially in elderly patients or those with multiple comorbidities. Objective To evaluate the efficacy and safety of rabeprazole‐amoxicillin dual therapy in H pylori‐positive elderly patients or those with multiple comorbidities. Methods From November 2013 to May 2017, the clinical data of H pylori‐positive patients ≥60 years old or with multiple comorbidities were collected and reviewed. All patients were given rabeprazole 10 mg three times a day and amoxicillin 1000 mg thrice a day (RA dual therapy) for 14 days as first‐line treatment. H pylori eradication was evaluated by 13C‐urea breath test 6 weeks after treatment. Adverse effects were recorded. Results A total of 198 patients were enrolled, including 116 elderly patients and 82 patients with multiple comorbidities. Successful eradication was achieved in 90.9% (180/198, 95% CI: 86.1%‐94.2%) patients. Adverse effects, which were mainly mild (referring to skin rash, abdominal pain, and diarrhea), occurred in 22 patients (22/198, 11.1%) and resolved spontaneously. Conclusion Dual therapy composed of rabeprazole and amoxicillin as a first‐line treatment appears to be effective and safe for H pylori infection in elderly patients or those with multiple comorbidities. Additional studies are needed to optimize the regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Rabeprazole‐amoxicillin dual therapy as first‐line treatment for H pylori eradication in special patients: A retrospective, real‐life study

Gao

Deng

et al. 2020

Helicobacter

View full text Add to dashboard Cite

show abstract

“…With the reference to the prevalence of primary fluoroquinolone resistance is higher than 15% in Asia (China, Iran, Japan, Pakistan) and Russia, bismuth subsalicylate was added to the combination in our study (23). Kahramanoğlu et al (24) also found that a 14-day levofloxacin-containing BQT was somewhat more efficient than levofloxacin-containing triple therapy. Although the MBCT regimes had the highest compliance, both the 10day and 14-day MBCT protocols were a lower eradication rate than BQT regimens in our study.…”

Section: Discussionmentioning

confidence: 68%

Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?

Etık

Sezer

Suna

et al. 2019

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: The duration of Helicobacter pylori (H. pylori) eradication therapy as a range (e.g., 10-14 days) is an ignored problem. There is no any particular treatment duration described in current guidelines, and the conditions for when to use 10-day therapy vs. 14-day therapy have not been elucidated. The aim of this study is to determine an effective and reliable H. pylori treatment duration in clinical practice. There were four different treatment modalities administered to groups, and success rates were compared. Materials and Methods: Patients were eligible to participate in the study if they had a biopsy-proven H. pylori infection. Each patient was randomly assigned to one of the four treatment groups according to a predetermined sequence: 14-day or 10-day bismuth-containing quadruple therapy (BQT) groups and 14-day or 10-day moxifloxacin-bismuth-combined treatment (MBCT) groups. Results: A total of 216 patients (54 per group) were enrolled. Two-hundred six patients (95.3%) completed therapy. There was no significant difference in the eradication rates between those patients who received . The 14-BQT protocol had the highest eradication rate, the MBCT regimes had the highest compliance, and the 10-MBCT protocol had the poorest results for H. pylori eradication. The posttreatment questionnaire on adverse effects identified nausea/vomiting as the most common side effect (35.7%). Conclusion: Overall, the results of our study suggest that shortening the BQT protocol duration to 10 days does not weaken the H. pylori eradication rate. Moreover, quinolone-containing therapies with the lowest eradication rate among the groups should not be offered as a salvage treatment in case of the BQT failure.

show abstract

“…50 A comparison of levofloxacin-containing triple therapy with levofloxacin-containing BQT and standard BQT from Turkey found bismuth-containing regimens to be superior. 51 An American study found modified dual therapy consisting of higher doses of PPI reached comparative eradication rates with BQT, without significant adverse effects. 52…”

Section: B Is Muthmentioning

confidence: 99%

Treatment of Helicobacter pylori infection in 2018

et al. 2018

View full text Add to dashboard Cite

Treatment options for the eradication of Helicobacter pylori continue to evolve. There have been many guidelines for H. pylori treatment published, which may lead to some confusion. However, most are in agreement with the most recent iteration of the Maastricht treatment guidelines. Triple therapy is still the most frequently used treatment, especially in areas of low clarithromycin resistance. Its best results are achieved when taken for a minimum of 10 days and with high-dose acid suppression. Quadruple therapy is gaining in popularity particularly in areas with increasing resistance to standard triple therapy. Whether three antibiotics, or bismuth and two antibiotics are used, excellent eradication rates are achieved, albeit with increased side effects. Levofloxacin second-line therapy is widely used; however bismuth, when available, is an increasingly successful option. Sequential therapy is challenging in terms of compliance and is no longer recommended. This past year witnessed a notable increase in the number of studies based on antimicrobial susceptibility testing and tailored eradication therapy, reflecting the role of culture-guided treatment, which may well represent the future of H. pylori treatment and prevent the inappropriate use of antibiotics.

show abstract

Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen

Cited by 13 publications

References 33 publications

Rabeprazole‐amoxicillin dual therapy as first‐line treatment for H pylori eradication in special patients: A retrospective, real‐life study

Rabeprazole‐amoxicillin dual therapy as first‐line treatment for H pylori eradication in special patients: A retrospective, real‐life study

Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?

Treatment of Helicobacter pylori infection in 2018

Contact Info

Product

Resources

About